Cree BAC - Search Results

1

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.

Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study Investigators. Marignier R, et al. Among authors: cree bac. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212/NXI.0000000000000978. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33771837 Free PMC article. Clinical Trial.

2

Neuromyelitis optica.

Cree BA, Goodin DS, Hauser SL. Cree BA, et al. Semin Neurol. 2002 Jun;22(2):105-22. doi: 10.1055/s-2002-36534. Semin Neurol. 2002. PMID: 12524556 Review.

3

An open label study of the effects of rituximab in neuromyelitis optica.

Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. Cree BA, et al. Neurology. 2005 Apr 12;64(7):1270-2. doi: 10.1212/01.WNL.0000159399.81861.D5. Neurology. 2005. PMID: 15824362 Clinical Trial.

4

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.

Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.

5

Acute transverse myelitis: is the "idiopathic" form vanishing?

Cree BA, Wingerchuk DM. Cree BA, et al. Neurology. 2005 Dec 27;65(12):1857-8. doi: 10.1212/01.wnl.0000194615.51750.f8. Neurology. 2005. PMID: 16380606 No abstract available.

6

Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays.

Lalive PH, Menge T, Barman I, Cree BA, Genain CP. Lalive PH, et al. Neurology. 2006 Jul 11;67(1):176-7. doi: 10.1212/01.wnl.0000223346.09426.34. Neurology. 2006. PMID: 16832107 No abstract available.

7

Neuromyelitis optica: diagnosis, pathogenesis, and treatment.

Cree B. Cree B. Curr Neurol Neurosci Rep. 2008 Sep;8(5):427-33. doi: 10.1007/s11910-008-0066-2. Curr Neurol Neurosci Rep. 2008. PMID: 18713580 Review.

8

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA. Jacob A, et al. Arch Neurol. 2008 Nov;65(11):1443-8. doi: 10.1001/archneur.65.11.noc80069. Epub 2008 Sep 8. Arch Neurol. 2008. PMID: 18779415

9

Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis.

Green AJ, Cree BA. Green AJ, et al. J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):1002-5. doi: 10.1136/jnnp.2008.166207. Epub 2009 May 21. J Neurol Neurosurg Psychiatry. 2009. PMID: 19465415

10

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group. Hawker K, et al. Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867. Ann Neurol. 2009. PMID: 19847908 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

228 results

Search Page